Diabetes stocks buy
Founded in by brothers Tom and David Gardner, The Motley Fool helps millions of people attain financial freedom through our website, podcasts, books, newspaper column, radio show, and premium investing services.
Looking to add a few thrills to your investing portfolio? Small-cap biotech stocks should be a good place to start. They come with significant risks, but the potential rewards are great. Here's why Celldex Therapeutics NASDAQ: CLDXGeron NASDAQ: GERNHalozyme Therapeutics NASDAQ: HALOLexicon Pharmaceuticals NASDAQ: LXRXand Synergy Pharmaceuticals NASDAQ: Celldex was severely wounded after its experimental brain cancer drug Rintega failed in a late-stage clinical study.
However, the small biotech was only down, not out. Celldex's pipeline includes five other candidates.
The most important of these right now is glembatumumab vedotin "glemba". A registrational phase 2 study evaluating glemba in treating triple-negative breast cancer is under way, and final data collection for the primary outcome measure of the study wraps up in late Celldex should announce results from a phase 2 study of glemba in treating uveal melanoma early this year.
Good news from any of these clinical trials should help Celldex rise from the ashes. Geron doesn't have multiple pipeline candidates like Celldex does.
Testing continued in the myelofibrosis study with a higher dosage of the drug. All eyes will be on updates from these two clinical studies in the second quarter of It's hard to overstate the importance of these results for Geron. Positive news should send the stock soaring, but poor results could deliver a blow from which it would probably be difficult for the biotech to recover.
Halozyme has already announced both good news and bad news in The bad news was that revenue will be lower than expected. There are at least a couple of potential catalysts for Halozyme this year.
The company plans to present more data for PEGPH20 in the first half of Halozyme could also get good news from a decision by the U. Food and Drug Administration FDA for a subcutaneous formulation of Rituxan in June. The biggest opportunity for Halozyme, though, remains in the future. However, the FDA pushed back its decision until Feb.
That's only the first big event for Lexicon this year, though. Lexicon also will report results from john campbell oil trading system phase 1 study of LX in treating diabetes this year.
The biotech plans to launch the drug later in the first quarter.
Diabetes stocks buy on these results, Synergy plans to file for U. It's possible the FDA could make a decision on the additional indication before the end of the year. If not, a decision should be forthcoming by early Synergy's stock has given up some of its diabetes stocks buy gains made in Considering the large potential market for Trulance, though, the stock should have plenty of room to move higher with a successful launch.
Every one of these small-cap biotech stocks carries plenty of risk. Money management stock trading .pdf think Synergy is the most de-risked, though, after the FDA approval of Trulance for CIC.
The Best Diabetes or Insulin Stock Plays? NVO, LLY, SNY, MRK, AMLN, PODD & MNKD : Small Stock Gems
If you could only pick one of these stocks to buy, I'd go with Synergy. Keith Speights owns shares of Celgene.
Medicare's National Mail-Order Program for Diabetes Testing Supplies: American Diabetes Association®
The Motley Fool owns shares of and recommends Celgene. The Motley Fool recommends Celldex Therapeutics and Johnson and Johnson. The Motley Fool has a disclosure policy. Keith began writing for the Fool in and focuses primarily on healthcare investing topics.
Buy or Sell TNDM (Tandem Diabetes Care) stocks?
His background includes serving in management and consulting for the healthcare technology, health insurance, medical device, and pharmacy benefits management industries. Skip to main content The Motley Fool Fool. Premium Advice Help Fool Answers Contact Us Login. Latest Stock Picks Stocks Premium Services. Stock Advisor Flagship service.
Rule Breakers High-growth stocks. Income Investor Dividend stocks.
10 Best Stocks to buy for the long term
Hidden Gems Small-cap stocks. Inside Value Undervalued stocks. Learn How to Invest.
Credit Cards Best Credit Cards of Best Credit Card Sign-Up Bonuses Best Balance-Transfer Credit Cards Best Travel Credit Cards Best Cash-Back Credit Cards Best No-Annual-Fee Credit Cards Best Small Business Credit Cards. Mortgages Compare Mortgage Rates Get Pre-Approved How Much House Can I Afford? Taxes How to Reduce Your Taxes Deductions Even Pros Overlook Audit-Proof Your Tax Return What Info Should I Keep?
Helping the World Invest — Better. How to Invest Learn How to Invest.
Personal Finance Credit Cards Best Credit Cards of Best Credit Card Sign-Up Bonuses Best Balance-Transfer Credit Cards Best Travel Credit Cards Best Cash-Back Credit Cards Best No-Annual-Fee Credit Cards Best Small Business Credit Cards.
Jan 25, at 4: Prev 1 2 3 4 Next. Motley Fool push notifications are finally here Allow push notifications to help you stay on top of Breaking investing news Earnings coverage Market movers Special offers and more Subscribe to notifications You can unsubscribe at any time.